Trial Profile
Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2019
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Interstitial cystitis
- Focus Therapeutic Use
- 24 Feb 2018 Status changed from active, no longer recruiting to completed.
- 01 Mar 2017 Planned End Date changed from 1 May 2018 to 1 Jul 2017.
- 01 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 1 May 2017.